Market Overview

Stifel Nicolaus Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces $36 Price Target

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for RYTM

DateFirmActionFromTo
Jul 2019UpgradesHoldBuy
Sep 2018Initiates Coverage OnHold
Sep 2018ReinstatesOverweight

View More Analyst Ratings for RYTM
View the Latest Analyst Ratings

Posted-In: News Initiation Analyst Ratings

 

Related Articles (RYTM)

Latest Ratings

StockFirmActionPT
IGMSPiper JaffrayInitiates Coverage On26.0
IGMSGuggenheimInitiates Coverage On30.0
DDOGBarclaysInitiates Coverage On45.0
BYNDWells FargoInitiates Coverage On125.0
DDOGJP MorganInitiates Coverage On45.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

A Peek Into The Markets: US Stock Futures Gain Ahead Of Economic Data

46 Biggest Movers From Yesterday